Oncolytic Adenovirus Market Snapshot (2023 to 2033)

The global oncolytic adenovirus market is expected to garner a market value of USD 121.30 Billion in 2023 and is expected to accumulate a market value of USD 250 Billion by registering a CAGR of 7.5% in the forecast period 2023 to 2033. Growth of the oncolytic adenovirus market can be attributed to the Increasing prevalence of oncology globally coupled with a surge in Research and Development efforts to develop novel oncology therapeutics. These are the major driving factors for the market. The market for oncolytic adenovirus registered a CAGR of 4.9% in the historical period 2018 to 2022

Moreover, the presence of various organizations that support immunotherapy research is also expected to fuel market growth. For instance, Parker Institute for Cancer Immunotherapy collaborated with researchers and industry leaders to develop breakthrough immune therapies for cancer.

According to the Global Cancer Observatory, the US reported around 2,281,658 cancer cases in 2020 and 612,390 cancer-related deaths. The most common malignancies affecting the US population are breast, prostate, lung, and colorectal. In addition, according to the Cancer Council, Australia reported 150,000 new cancer cases with 50,000 deaths in 2020. Thus, the surge in the prevalence of malignant tumor cases is anticipated to accelerate market expansion in the coming years.

Report Attribute Details
Expected Market Value (2023) USD 121.30 Billion
Anticipated Forecast Value (2033) USD 250 Billion
Projected Growth Rate (2023 to 2033) 7.5% CAGR

Exclusive Offer: 30% Off on Regional Reports

Get a free sample report and customize your regions for a 30% discount on your regional report!

2017 to 2022 Oncolytic Adenovirus Market Demand Analysis vs. Forecast 2023 to 2033

According to market research and competitive intelligence provider Future Market Insights- the market for oncolytic adenovirus reflected a value of 4.9% during the historical period, 2017 to 2022.

The increasing prevalence of different types of cancers is a significant factor driving the market's growth. In addition, the presence of various immunotherapies to treat cancer at different stages in creating a positive demand for oncolytic adenovirus. Furthermore, the COVID-19 pandemic affected the research and development activities related to oncolytic adenovirus due to the disruption in the supply chain demand globally.

Thus, the market for Oncolytic adenovirus is expected to register a CAGR of 7.5% in the forecast period 2023 to 2033.

Which are Some Prominent Drivers of Oncolytic Adenovirus Market?

Improving patient outcomes by advancing the science and application of oncolytic adenovirus

The presence of various government and non-government organizations that create awareness and promote research is augmenting market expansion. For instance, Cancer Research Institute funded more than 120 clinical trials and invested around USD 474 Billion in research. Moreover, the Society for Immunotherapy of Cancer(SITC) is engaged in improving patient outcomes by advancing the science and application of oncolytic adenovirus. These organizations are working with scientists and researchers to discover novel treatment regimens of immune therapy.

Furthermore, increasing funding for the development of novel treatments is expected to boost Research and Development activities to develop cancer immunotherapy. For instance, in June 2022, Stanford scientists received USD 13 Billion from Cancer Grand Challenges, a funding initiative by Cancer Research UK and the US National Cancer Institute. This funding is awarded for the development of next-generation immunotherapies, the study of extrachromosomal DNA, and the investigation of early-stage malignancies.

Increasing approval of novel immunotherapies is anticipated to propel the market growth over the forecast period. From 2020 to 2022, the USA FDA has approved various anti-PD-1/L1 antibodies such as nivolumab, atezolizumab, avelumab, dostarlimab, and others for the treatment of NSCLC, renal cell carcinoma, melanoma, breast, prostate malignancies, and others. The higher approvals of immunotherapeutic agents have propelled the market growth.

Strategic initiatives by leading players propelling the market growth

Various Strategic initiatives undertaken by leading players are also expected to facilitate the market demand. For instance, in August 2022, BioNTech SE and Genmab A/S expanded their strategic collaboration for the development and launch of new immune therapies for the treatment of various cancer forms. Moreover, in March 2022, Merck & Co., Inc announced the approval of KEYTRUDA from the US FDA. KEYTRUDA is an anti-PD-1 therapy for treating advanced endometrial carcinoma.

However, side effects associated with immunotherapy will likely hamper the cancer treatment prescription rate. The available therapies are associated with several adverse effects, such as pain, insomnia, fatigue, nausea, and gastrointestinal conditions. These adverse effects impact the overall quality of life of patients and the management of these adverse effects incurs extra costs. In addition, prolonged consumption of immunotherapeutic drugs may cause severe damage to the organs and increase the incidence of organ failure cases.

Get Brochure on Email

Almost 80% of our clients request uniquely tailored intelligence.

What are the Challenges Faced by the Oncolytic Adenovirus Market?

Antiviral immune response creating challenges for the oncolytic adenovirus market

Although oncolytic adenovirus has remarkable antitumor potency, it is confronted with tough challenges such as antiviral immune response and obstruction of the tumor microenvironment (TME). This has led to a significant debate on the efficiency and application of oncolytic adenovirus for cancer treatment.

Furthermore, the time taken for approval of therapies and medications for cancer is derailing the progress of the market. In addition, the efficiency of drugs and their long-lasting impact is still being tested. All these factors are hampering the growth of the oncolytic adenovirus market.

Region-Wise Insights

Strong Presence of Key Players in North America accelerating the Growth of the Oncolytic Adenovirus Market?

Government and non-government organizations supporting research activities for oncolytic adenovirus in North America

In 2022, North America led the overall market in terms of revenue due to the presence of a large number of leading players coupled with various Strategic initiatives undertaken by them. Moreover, the increase in disease prevalence, various government and non-government organizations promoting research activities for cancer immunotherapy, and the increasing approval of novel drugs are fueling the regional market growth. For instance, in April 2022, the US FDA approved Opdivo (nivolumab) for treating NSCLC in adult patients.

Thus, North America is expected to possess a 43% market share for the oncolytic adenovirus market in 2023.

Regulatory Approvals Supporting Growth for Oncolytic Adenovirus Market in the Asia Pacific?

Investments in research and healthcare infrastructure create lucrative opportunities for the oncolytic adenovirus market

Asia Pacific is projected to witness the fastest growth rate over the forecast period. The increase in the geriatric population, a large patient base of targeted diseases, and improving healthcare infrastructure are some of the primary factors driving the growth.

Moreover, the rising regulatory approvals of immune therapies in the region are also contributing region’s expansion. For instance, from 2020 to 2022, the National Medical Products Administration of China approved Pembrolizumab and Durvalumab to treat esophageal cancer and SCLC.

Thus, Asia Pacific is expected to possess a 39% market share for the oncolytic adenovirus market in 2023.

Check Free Sample Report & Save 40%!

Select your niche segments and personalize your insights for smart savings. Cut costs now!

Category-Wise Insights

Prevalence of Lung Malignancies Creating Lucrative Opportunities for Oncolytic Adenovirus?

Product approval for treating lung cancer boosting segment growth

The rising prevalence of lung malignancies, increasing adoption of immunotherapy, rise in awareness programs, and presence of a robust pipeline of investigational candidates are some of the key factors expected to drive the segment's growth. Furthermore, rising product approval and product launches fueling the demand forward. For instance, in October 2021, the US FDA approved Tecentriq (atezolizumab) to treat stage II and stage III NSCLC.

Thus, lung cancer is expected to possess a 35% market share for oncolytic adenovirus in 2023.

Market Competition

Key players in the oncolytic adenovirus market are Amgen, Sorrento Therapeutics, Transgene SA, Oncolys BioPharma, Targovax, Lokon Pharma, Vyriad, TILT Biotherapeutics, CG Oncology Inc, VCNBiosciences, DNAtrix, Replimune Group Inc

  • In May 2022, Amgen, a key player in the oncolytic adenovirus market stated that Oncolytic immunotherapy aims to build on this potential by using genetically modified viruses to target tumors in two important and complementary ways.
  • Oncolys BioPharma, another key player in the oncolytic adenovirus market, is investing in research and development for innovative medication for oncolytic adenovirus.

Report Scope

Report Attribute Details
Market Value in 2023 USD 121.30 Billion
Market Value in 2033 USD 250 Billion
Growth Rate CAGR of 7.5% from 2023 to 2033
Base Year for Estimation 2021
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in USD Billion and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered Type, Application, Region
Regions Covered North America; Latin America; Western Europe; Eastern Europe; Asia Pacific Excluding Japan; Japan; Middle East and Africa (MEA)
Key Countries Profiled The USA, Canada, Brazil, Argentina, Germany, The UK, France, Spain, Italy, Nordics, BENELUX, Australia & New Zealand, China, India, Association of Southeast Asian Nations, GCC Countries, South Africa
Key Companies Profiled Amgen; Sorrento Therapeutics; Transgene SA; Oncolys BioPharma; Targovax; Lokon Pharma; Vyriad; TILT Biotherapeutics; CG Oncology Inc; VCNBiosciences; DNAtrix; Replimune Group Inc
Customization Available Upon Request

Key Segments Profiled in the Oncolytic Adenovirus Industry Survey

By Type:

  • HSV-based Oncolytic Viruses
  • Adenoviruses-based Oncolytic Viruses
  • Others

By Application:

  • Melanoma
  • Prostate Cancer
  • Breast Cancer
  • Ovarian Cancer
  • Lung Cancer
  • Others

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa (MEA)
Table of Content
  • 1. Executive Summary | Oncolytic Adenovirus Market
  • 2. Market Overview
  • 3. Market Background
  • 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
  • 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Types
    • 5.1. HSV-based Oncolytic Viruses
    • 5.2. Adenoviruses-based Oncolytic Viruses
    • 5.3. Others
  • 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Applications
    • 6.1. Melanoma
    • 6.2. Prostate Cancer
    • 6.3. Breast Cancer
    • 6.4. Ovarian Cancer
    • 6.5. Lung Cancer
    • 6.6. Others
  • 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
    • 7.1. North America
    • 7.2. Latin America
    • 7.3. Europe
    • 7.4. South Asia
    • 7.5. East Asia
    • 7.6. Oceania
    • 7.7. Middle East & Africa (MEA)
  • 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
  • 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
  • 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
  • 11. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
  • 12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
  • 13. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
  • 14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
  • 15. Key Countries Market Analysis
  • 16. Market Structure Analysis
  • 17. Competition Analysis
    • 17.1. Amgen
    • 17.2. Sorrento Therapeutics
    • 17.3. Transgene SA
    • 17.4. Oncolys BioPharma
    • 17.5. Targovax
    • 17.6. Lokon Pharma
    • 17.7. Vyriad
    • 17.8. TILT Biotherapeutics
    • 17.9. CG Oncology Inc.
    • 17.10. VCNBiosciences
    • 17.11. DNAtrix
    • 17.12. Replimune Group Inc.
  • 18. Assumptions & Acronyms Used
  • 19. Research Methodology

Frequently Asked Questions

At what rate did the Oncolytic adenovirus market flourish from 2017 to 2022?

From 2017 to 2022, the oncolytic adenovirus market grew at a CAGR of 4.9%

What will be the growth rate of the global Oncolytic adenovirus market during the forecast period?

The global oncolytic adenovirus market is expected to grow with a 7.5% CAGR from 2023 to 2033.

What will be the projected market size of the Oncolytic adenovirus market by 2033?

As of 2033, the oncolytic adenovirus market is expected to reach USD 250 Billion

Which type of application is expected to dominate the global Oncolytic adenovirus market during 2033?

Lung cancer is expected to possess a 35% market share for oncolytic adenovirus in 2023.

How is the North America Oncolytic adenovirus market projected to grow in 2033?

North America is expected to possess a 43% market share for the oncolytic adenovirus market in 2023.

How is the Asia Pacific Oncolytic adenovirus market projected to grow in 2033?

Asia Pacific's oncolytic adenovirus market size is expected to possess a 39% market share in 2023.

Recommendations

Stent Graft Balloon Catheter Market
Estimated Size, 2025 USD 1,047.9 million
Projected Size, 2035 USD 2,194.9 million
Value-based CAGR (2025 to 2035) 6.8%
Central Venous Catheter Market
Estimated Size, 2024 USD 2,861.0 million
Projected Size, 2034 USD 5,436.8 million
Value-based CAGR (2024 to 2034) 6.6%
Continuous Peripheral Nerve Block Catheter Market
Market Estimated Size in 2023 USD 585.6 million
Projected Market Value in 2033 USD 1,058.6 million
Value-based CAGR from 2023 to 2033 6.1%
AIDS Related Primary CNS Lymphoma Market
Market Value (2022) USD 1,127 Million
Market Forecast Value (2032) USD 2,145.52 Million
Market CAGR (2022 to 2032) 6.65%

Explore Therapy Area Insights

View Reports
Trusted By
Future Market Insights

Oncolytic Adenovirus Market

Schedule a Call